Verastem (NASDAQ:VSTM) has been assigned a $17.00 price target by equities researchers at Cantor Fitzgerald in a research note issued to investors on Sunday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 292.61% from the company’s current price.

VSTM has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Verastem in a report on Wednesday, November 8th. Cann restated a “buy” rating and set a $15.00 price objective on shares of Verastem in a report on Sunday. Oppenheimer restated a “buy” rating and set a $6.00 price objective on shares of Verastem in a report on Thursday, October 12th. Zacks Investment Research cut Verastem from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, ValuEngine cut Verastem from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $8.91.

Shares of Verastem (NASDAQ:VSTM) opened at $4.33 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. Verastem has a twelve month low of $1.08 and a twelve month high of $5.71.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.29). equities research analysts predict that Verastem will post -1.74 earnings per share for the current year.

In other Verastem news, Director Timothy J. Barberich bought 60,538 shares of the stock in a transaction on Tuesday, December 5th. The shares were bought at an average price of $3.95 per share, with a total value of $239,125.10. Following the purchase, the director now directly owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.51% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alpine Woods Capital Investors LLC bought a new stake in shares of Verastem in the 2nd quarter valued at approximately $109,000. Cubist Systematic Strategies LLC bought a new stake in shares of Verastem in the 3rd quarter valued at approximately $136,000. Northern Trust Corp grew its stake in shares of Verastem by 40.3% in the 2nd quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 21,178 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Verastem in the 3rd quarter valued at approximately $195,000. Finally, OxFORD Asset Management LLP bought a new stake in shares of Verastem in the 2nd quarter valued at approximately $234,000. 34.24% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/verastem-vstm-pt-set-at-17-00-by-cantor-fitzgerald/1757085.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.